Accell has commenced two Phase III clinical trials testing the efficacy of a new drug for prevention of major cardiovascular events in risk group patients. Thirty Russian sites managed by Accell will participate in both studies. The Sponsor of the trial is a major pharmaceutical company developing a number of therapies for slowing down and prevention of disease progression in patients with cardiovascular, metabolic and kidney diseases and we are working with partner CROs on this extensive multinational clinical study.